Clinical Trial

An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study

Study acronym: DiRECT
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This study compares treatment outcomes between patients of African American/Black (AA) ancestry and European American/White (EA) ancestry currently receiving immune checkpoint inhibitor treatment. Collecting samples of blood and saliva and health and treatment information from racially diverse patients receiving immune checkpoint inhibitor treatment over time may help doctors better understand health care disparities among all cancer patients.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-05-02; most recent amendment 2026-03-11.
Status change: Recruiting → Active, Not Recruiting 2026-03-11
Trial Details
NCT Number NCT05364086
Lead Sponsor University of Rochester NCORP Research Base
Collaborators: National Cancer Institute (NCI)
Conditions Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Enrollment 2,100 participants
Start Date 2022-04-26
Primary Completion 2026-10-31 (estimated)
Study Completion 2030-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-13